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Abstract
Background: Normal osteoclasts resorb bone by secretion of acid and proteases. Recent studies of patients with loss 
of function mutations affecting either of these processes have indicated a divergence in osteoclastic phenotypes. 
These difference in osteoclast phenotypes may directly or indirectly have secondary effects on bone remodeling, a 
process which is of importance for the pathogenesis of both osteoporosis and osteoarthritis. We treated human 
osteoclasts with different inhibitors and characterized their resulting function.
Methods: Human CD14 + monocytes were differentiated into mature osteoclasts using RANKL and M-CSF. The 
osteoclasts were cultured on bone in the presence or absence of various inhibitors: Inhibitors of acidification 
(bafilomycin A1, diphyllin, ethoxyzolamide), inhibitors of proteolysis (E64, GM6001), or a bisphosphonate (ibandronate). 
Osteoclast numbers and bone resorption were monitored by measurements of TRACP activity, the release of calcium, 
CTX-I and ICTP, as well as by counting resorption pits.
Results: All inhibitors of acidification were equally potent with respect to inhibition of both organic and inorganic 
resorption. In contrast, inhibition of proteolysis by E64 potently reduced organic resorption, but only modestly 
suppressed inorganic resorption. GM6001 alone did not greatly affect bone resorption. However, when GM6001 and 
E64 were combined, a complete abrogation of organic bone resorption was observed, without a great effect on 
inorganic resorption. Ibandronate abrogated both organic and inorganic resorption at all concentrations tested [0.3-
100 μM], however, this treatment dramatically reduced TRACP activity.
Conclusions: We present evidence highlighting important differences with respect to osteoclast function, when 
comparing the different types of osteoclast inhibitors. Each class of osteoclast inhibitors will lead to different alterations 
in osteoclast quality, which secondarily may lead to different bone qualities.
Background
Bone remodeling is an important and integrated part of
the processes controlling the age and quality of the bone
matrix [1]. Bone remodeling is mediated by two cell
types: Osteoclasts, which are the only cells with the abil-
ity to degrade the calcified bone matrix, and osteoblasts,
which are bone-forming cells [1]. Bone resorption is
always followed by bone formation in a tightly balanced
manner referred to as coupling [2,3]. Recent studies in
humans with mutations altering the ability of osteoclasts
to perform bone resorption have indicated that osteo-
clasts, in addition to their role in bone resorption, play
important roles in orchestrating bone formation [3-6].
Recent studies have furthermore demonstrated that
osteoclasts on plastic (non-resorbing osteoclasts) secrete
signals which induce bone formation [7,8]. It may there-
fore be speculated that the phenotype of osteoclasts is
highly important for the cell-to-cell signaling between
osteoclasts and osteoblasts, and may have secondary
effects on bone formation during bone remodeling [4,5].
Bone resorption is initiated by osteoclasts forming a
sealing zone and ruffled border at their interface with
bone. Through the ruffled border the osteoclasts secrete
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Page 2 of 13hydrochloric acid [9] to dissolve the inorganic matrix, for
which low pH is required. The secretion of protons from
osteoclasts is an active process, which requires activity of
the osteoclast-specific vacuolar ATPase (V-ATPase) con-
taining the a3 subunit [10,11]. Chloride transport
through the ruffled border occurs via the chloride-proton
antiporter ClC-7 [12-15], and thereby electroneutrality
across the membrane is maintained. Elimination of either
of the two process leads to complete loss of acid secretion
and hence neither the inorganic matrix nor the organic
matrix are dissolved [15]. Loss of function of either the
osteoclast-specific V-ATPase a3 subunit or ClC-7 leads to
the osteopetrotic human disorders: autosomal recessive
osteopetrosis (ARO) or autosomal dominant osteopetro-
sis type II (ADOII) [12,16-19]. Osteopetrosis in both man
and mice is characterized by a high bone mass pheno-
type, due to lack of osteoclast function as described above
[10-15,20].
In order to generate protons, the presence of carbonic
anhydrase II (CAII) is essential. It catalyzes the conver-
sion of H2O and CO2 into H2CO3, which then is ionized
into H+ and HCO3- [21-23]. Mutations in CAII can also
cause osteopetrosis due to non-functional osteoclasts
[21]. The HCO3- ions are exchanged for Cl- through an
anion exchanger, AE2, located in the basolateral mem-
brane, leading to continued availability of Cl- for acidifica-
tion of the resorption lacuna [24-26].
Osteoclasts produce proteases, of which cysteine pro-
teinase cathepsin K has proven to be the most important
[27-30], aiding the degradation of the organic bone
matrix. Osteoclasts secrete cathepsin K into the resorp-
tion lacunae, resulting in type I collagen matrix cleavage
[27-30]. Cathepsin K gives rise to specific degradation
products like C-terminal cross-linking telopeptide of type
I collagen (CTX-I), which can be used for measurements
of bone resorption [31]. Lack of cathepsin K results in
pycnodysostosis, a disease characterized by high bone
mass and skeletal deformities [27-30]. Matrix metallopro-
teinases (MMPs) have also been shown to participate in
bone resorption [32-34], during which, MMP activity is
known to give rise to a specific degradation fragment, C-
terminal telopeptide of type I collagen (ICTP) [31]. The
roles of MMPs appear, however, to be dependent on the
type of bone the osteoclasts are to resorb, as MMP activ-
ity have been shown to have higher importance for
resorption of flat bones compared to long bones [35-38].
Further complicating the understanding of the precise
action and roles of these proteases is the fact that under
some circumstances the activity of MMPs is masked by
the activity of cathepsin K [33].
In this study we investigated the function of human
osteoclasts in response to inhibited degradation of either
the organic or inorganic bone matrix. For inhibition of
acidification two independent V-ATPase inhibitors, bafi-
lomycin A1 [39] and diphyllin [40], were used. A third
acidification blocker used was ethoxyzolamide, inhibiting
CAII [41]. For inhibition of organic resorption the broad-
spectrum cysteine proteinase inhibitor, E64 [42], and the
broad-spectrum MMP inhibitor, GM6001 [33], were
used. Finally, ibandronate, a nitrogen-containing bisphos-
phonate [43], was tested to evaluate the effect of general
osteoclast inhibition. Significant differences in the
resorption profile of osteoclasts were seen in response to
application of the different types of inhibitors.
Methods
Compounds
Bafilomycin was purchased from Tocris, diphyllin was
purchased from Bioduro, E64 was purchased from Cal-
biochem, GM6001 was purchased from AM Scientific,
and ibandronate and ethoxyzolamide were purchased
from Sigma-Aldrich. All the remaining chemicals were
from Sigma-Aldrich and the culture media were from
Invitrogen, unless otherwise specified.
Isolation of CD14+ human monocytes and osteoclast 
differentiation
CD14+ human monocytes were isolated as previously
described [44]. Briefly, the monocytes were separated
from human peripheral blood by centrifugation on a
Ficoll-Paque gradient (Amersham Pharmacia), and mag-
netically sorted using a CD14+ magnetic bead isolation
kit (Dynabeads M-450, Dynal Biotech). The cells were
seeded in 75 cm2 flasks and cultured in minimum essen-
tial medium alpha (αMEM) containing 10% fetal bovine
serum, 100 units/ml penicillin, 100 μg/ml streptomycin,
25 ng/ml of macrophage colony stimulating factor (M-
CSF) (R&D Systems) and 25 ng/ml receptor activator of
NFκB ligand (RANKL) (R&D Systems) for 10-12 days.
Osteoclast culture
When multinucleated (>3 nuclei), actin-ring positive
osteoclasts were dominant in the differentiated osteoclast
cultures (10-12 days after seeding CD14+ isolated mono-
cytes), the mature osteoclasts were lifted for experiments
as previously described by Sorensen et al. [44]. The
mature osteoclasts were seeded on cortical bovine bone
slices (50.000 cells/bone slice), and cultured in the pres-
ence or absence of inhibitors.
Bafilomycin was tested in the concentration range [0-
30 nM], diphyllin in the concentration range [0-100 nM],
ethoxyzolamide in the concentration range [0-100 μM],
E64 in the concentration range [0-5 μM], GM6001 in the
concentration range [0-100 μM], the combination treat-
ment of E64 and GM6001 was tested in the concentration
ranges [0-(5 μM E64) + (100 μM GM6001)] and iban-
dronate was tested in the concentration range [0-100
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Page 3 of 13μM]. The choice of specific concentration ranges for the
individual inhibitors was based on previous studies
[6,33,36,40,44-46].
Medium was exchanged at day 2 after seeding. Super-
natants from day 5 were collected, and the various
resorption markers were measured in these.
All experiments with each of the individual inhibitors
were conducted three times or more. The presented data
are from one representative experiment for each inhibi-
tor. Number of replicates in each experiment equals five.
For further investigations of supernatants and resorbed
bone slices, the specific concentrations tested for the
individual inhibitors were chosen based on maximum
inhibition of bone resorption, without significant
decrease in cell viability.
Cortical bovine bone slices
Bone slices were cut from bone sticks (Nordic Bioscience
A/S), which originated from femoral cortical bone from
cows. The sticks were cut into slices with a thickness of
0.2 mm. The bone slices, which fitted into 96-wells, had a
diameter of approximately 6 mm.
Measurements of resorption
Organic bone resorption was measured by the release of
both CTX-I and ICTP during culture.
CTX-I concentrations in culture supernatants were
determined using CrossLaps for Culture (IDS Nordic)
according to the manufacturer's instructions.
Concentrations of ICTP were measured using the ICTP
EIA kit (Orion Diagnostica Denmark A/S) according to
the manufacturer's instructions. For background mea-
surements, medium from bone slices without cells was
utilized. To estimate low ICTP concentrations, an alter-
native standard curve to the suggested was generated,
using linear regression for the lowest concentrations in
the standard row.
The concentration of total calcium, as an indicator of
inorganic bone resorption, was measured in culture
supernatants utilizing an ADVIA 1800 machine (Sie-
mens). The principle of this measurement is a colorimet-
ric assay in which the compound Arsenazo III forms a
purple complex with calcium under acidic conditions. For
background measurements, medium from bone slices
without cells was utilized.
TRACP activity
Tartrate resistant acid phosphatase (TRACP) activity was
used as an indirect measure of osteoclast number [47,48].
TRACP activity was measured as previously described
[6]. Briefly, samples were incubated with TRACP reaction
buffer containing p-nitrophenyl phosphate and sodium
tartrate [6], for 1 hour at 37°C in the dark. Reaction was
stopped with the addition of 0.3 M NaOH. Absorbance
was measured in an ELISA reader at 405 nm with 650 nm
as the reference.
Pit staining and counting
Bone resorption was evaluated by examinations of the
resorbed bone area. Mature osteoclasts were cultured for
five days on bone slices after which the adherent cells
were removed using a cotton swab. The bone slices were
washed in distilled water, and pits were stained with
Mayer's hematoxylin (Bie & Berntsen A/S), followed by
washing in water and removal of excess dye with a cotton
swab. The resorbed area was measured using CAST-Grid
(Olympus). The results were shown as resorbed area rela-
tive to the total area of bone. Pictures of the stained
resorption pits were taken with an Olympus DP71 cam-
era (x10 magnification).
Cell viability
To assess cell viability, Alamar blue measurements were
performed according to the manufacturer's protocol
(Trek Diagnostics Systems). Briefly, Alamar blue was
diluted 1:10 in the cell culture medium, and the color
change was monitored carefully. When a switch from
blue to purple was observed, the color changes were mea-
sured using a plate reader (excitation wavelength 540 nm,
emission 590 nm). Alamar blue-containing medium
added to wells without cells was used as background.
Gelatinase zymography
MMP activity in culture supernatants was tested by
gelatinase zymography as previously described [49].
Briefly, samples were run on a SDS-PAGE with a gelatin
gel. The gel was subsequently incubated for 2 days in a 1%
Triton X-100 buffer to wash out the SDS and to restore
enzyme activity. The gel was stained with coomassie blue
followed by de-staining and pictures were taken. MMP-9
was used as a positive control.
Three individual gels were run and average MMP-9
band intensities were analyzed using ImageJ.
Calculation of IC50 values
The IC50 values for individual inhibitors were calculated
using Prism 3.0. For these calculations the vehicle was set
to 100% and all other data were represented as % of vehi-
cle plotted against log[Treatment]. IC50 values were cal-
culated using a nonlinear regression curve fit.
Statistics
Statistical analyses were performed using one-way analy-
sis of variance (ANOVA) followed by Dunnett's multiple
comparison tests to adjust for multiple statistical testing
against the control group. Statistical significance is indi-
cated by the number of asterisks, p < 0.05 = *, p < 0.01 = **
and p < 0.001***. Error bars on all graphs indicate stan-
dard error of mean (SEM). Relative intensities of bands in
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tion (SD).
Results
Inhibition of acidification results in equivalent inhibition of 
calcium release and collagen degradation
All three acidification inhibitors decreased the ability of
mature osteoclasts to resorb both inorganic and organic
bone matrix. As seen in Figure 1, bafilomycin A1, diphyl-
lin, and ethoxyzolamide all inhibited bone resorption
completely at the highest doses tested (bafilomycin 30
nM, diphyllin 100 nM and ethoxyzolamide 100 μM). The
IC50 values for inhibition of organic and inorganic
resorption for each of the three inhibitors are shown in
Table 1. From these results it is apparent that all three
acidification blockers inhibited the organic and inorganic
bone matrix degradation equally well (Table 1 and Figure
1A-F). Cell viability varied only slightly, which was unre-
lated to the effects on bone resorption (Figure 1G-I).
Apart from a decrease at the highest dose of diphyllin
(100 nM) and bafilomycin (30 nM), no other reduction in
TRACP activity was observed, indicating that mature
osteoclasts were present (data not shown).
As seen in Figure 2A and 2B, all the acidification block-
ers at the highest concentrations tested reduced the
resorbed bone area dramatically, as expected from the
reduced organic and inorganic bone resorption seen in
Figure 1 and previous studies [23,40,41,50].
Inhibition of cathepsin K potently reduces organic and 
modestly decreases inorganic resorption but increases 
resorbed bone area
E64, which inhibits cathepsin K, potently reduced organic
resorption by approximately 80% at concentrations of
0.56-5 μM (Figure 3A). In contrast, inorganic resorption
was reduced by approximately 40% in the same concen-
tration range (Figure 3D). Cell viability measurements
showed that the reduction in organic resorption was not
due to toxicity (Figure 3G), and measurements of TRACP
activity showed no decrease in the number of mature
osteoclasts (data not shown). As seen in Figure 2A and
2B, the resorbed bone surface for cells treated with E64 at
a concentration of 5 μM was significantly higher than for
vehicle-treated cells.
MMP-mediated bone degradation is a minor but normal 
part of bone resorption
Use of GM6001 to inhibit MMP-mediated resorption
produced a modest reduction in bone resorption of both
organic and inorganic matrix, but only at the highest con-
centration of the inhibitor (100 μM) (Figure 3B and 3E).
This effect was not caused by decreased cell viability or
decreased number of osteoclasts as measured by TRACP
activity (Figure 3H, and data not shown). When both
cathepsin K and MMP-mediated bone resorption was
inhibited, CTX-I release was completely abrogated at
concentrations: E64 [0.56 μM] + GM6001 [10 μM] and
above, indicating that both cathepsin K and MMP activi-
ties are important for bone resorption, with cathepsin K
playing the major role (Figure 3A-C). Measurements of
cell viability showed that decreased cell viability was not
the cause of decreased resorption (Figure 3I), but a slight
decrease in TRACP activity was seen after combination
treatment with the highest doses of E64 [5 μM] and
GM6001 [100 μM] (data not shown). A more pronounced
reduction in inorganic resorption was seen with simulta-
neous treatment with E64 and GM6001 than after either
treatment alone (Figure 3D-F). This reduction in inor-
ganic resorption, however, did not match the reduction in
organic resorption, with the IC50 value for organic
resorption being 20 times higher than for inorganic
resorption. Treatment with GM6001 at 100 μM did not
change the extent of resorbed bone area compared with
the area associated with vehicle-treated cells (Figure 2A
and 2B), which is in alignment with previously published
data [13]. In addition, following co-treatment of cells with
E64 [5 μM] and GM6001 [100 μM], the percentage of
resorbed bone area was not significantly different from
that seen with vehicle-treated cells (Figure 2B).
MMPs appear to compensate for the absence of cathepsin 
K
In the vehicle-treated condition a minor release of ICTP
fragments was observed (Figure 4A), indicating that a low
level of MMP-mediated resorption took place during
normal resorption. All the tested inhibitors, except E64,
had either no effect or inhibited the release of ICTP, with
GM6001 showing the most potent reduction (Figure 4A).
In contrast, inhibition with E64 strongly increased the
ICTP release (Figure 4A). Gelatinase zymography of cul-
ture supernatants of all tested inhibitors was performed
to evaluate MMP activity. As seen in figure 4B, MMP-9
activity was significantly increased with E64 treatment.
With all other treatments, MMP-9 activity was either
unaltered or significantly lowered (diphyllin and iban-
dronate) in comparison with vehicle (Figure 4B).
During treatment with GM6001, the osteoclasts
responded by secreting more types of MMPs (Figure 4B).
However, this was not followed by an increase in ICTP
release (Figure 4A).
Ibandronate potently inhibits both organic and inorganic 
resorption by reducing the number of mature osteoclasts
As seen in figure 5A and 5B, the bisphosphonate, iban-
dronate, strongly inhibited both organic and inorganic
bone resorption at all concentrations tested [0.3-100 μM].
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age of resorbed bone area (Figure 2A and 2B). Cultured
cells showed decreased viability when treated with iban-
dronate at concentrations of 30 μM and above, but at
concentrations from 0.3-10 μM cell viability was unaf-
fected or even slightly increased (Figure 5C). TRACP
activity was, however, strongly decreased at all concen-
trations tested, indicating a strong reduction in the num-
ber of mature osteoclasts.
Discussion
We investigated the differences and similarities between
inhibition of acidification and proteolysis as well as gen-
eral osteoclast inhibition, with respect to the resorptive
phenotype of the osteoclasts. We, for the first time, pres-
ent data suggesting that different classes of bone resorp-
tion inhibitors may produce different phenotypes of
human osteoclasts. We speculate that these divergent
phenotypes in some aspects may reflect osteoclast qual-
Figure 1 The effect of inhibiting the acidification processes during osteoclastic resorption. Mature human osteoclasts were seeded on bone 
slices and cultured for 5 days in the presence or absence of bafilomycin A1 (Bafi), diphyllin or ethoxyzolamide (Ethoxy). A-C) CTX-I release measured 
in culture supernatants. D-F) Calcium release measured in culture supernatants. G-I) Cell viability measured by Alamar Blue. All results are plotted as 
% of control. Statistical tests were performed by ANOVA with Dunnet's multiple comparison test against the vehicle group.
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bone formation through the coupling process. In the
present study, human osteoclasts derived from CD14+
monocytes were utilized, although it must be noted that
osteoclasts from other sources, for example bone mar-
row, might have given different resorption profiles [38],
which could be of interest to study in the future.
Bafilomycin A1 and diphyllin, both inhibitors of the V-
ATPase, and ethoxyzolamide, a CAII inhibitor, were all
used as inhibitors of acidification within the resorption
lacuna. All three compounds completely abrogated bone
resorption measured by all parameters (CTX-I, calcium,
ICTP and resorbed bone area). In addition, IC50 values
for inhibition of organic and inorganic bone resorption
were found to be equal for the individual inhibitors of
acidification (Table 1). Thus, inhibiting the acidification
processes attenuates bone resorption, without the possi-
bility of potential compensatory mechanisms in vitro
(Figure 6, middle panel). This is in alignment with previ-
ous publications [6,40,51].
IC50 values were not calculated for the proteolysis
blockers as these inhibitors individually did not inhibit
bone resorption completely. Instead, the maximum level
of inhibition of resorption was investigated. For treat-
ment with E64 inhibiting cathepsin K, organic resorption
was reduced to a level of 20% in comparison to vehicle-
treated osteoclasts, whereas inorganic resorption was
reduced to a level of 60%. This is in line with the role of
cathepsin K in degradation of the organic bone matrix
[29] (Figure 6, lower panel). A similar phenomenon was
Table 1: IC50 values for each acidification blocker on inhibition of organic and inorganic resorption
Treatment Organic resorption (CTX-I) Inorganic resorption (Calcium)
Bafilomycin 3.1 nM 5.7 nM
Diphyllin 9.1 nM 12.4 nM
Ethoxyzolamide 4.9 μM 8.8 μM
Figure 2 Evaluations of resorbed bone area by different types of osteoclast inhibitors. Mature human osteoclasts were seeded on bone slices 
and cultured for 5 days in the presence or absence of the indicated inhibitors. A) Pits were stained and pictures of the indicated conditions were taken. 
B) The stained pits were counted using CAST grid. Percent resorbed bone area was calculated and plotted. Statistical tests were performed by ANOVA 
with Dunnet's multiple comparison test against the vehicle group. Scale bars = 200 μm.
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although the overall level of inhibition was markedly
lower than for E64 treatment. As both cathepsin K and
MMPs are important for degradation of the organic
matrix, it can be speculated why inhibitors of these
enzymes also affect resorption of the inorganic matrix. In
the process of bone resorption, acidification and proteol-
ysis cannot be considered as two separate processes.
Under normal circumstances the two processes will
occur simultaneously, and if organic resorption is hin-
Figure 3 The effect of inhibiting proteolysis during osteoclastic resorption. Mature human osteoclasts were seeded on bone slices and cultured 
for 5 days in the presence or absence of E64, GM6001 or a combination of E64 and GM6001. A-C) CTX-I release measured in culture supernatants. D-
F) Calcium release measured in culture supernatants. G-I) Cell viability measured by Alamar Blue. All results are plotted as % of control. Statistical tests 
were performed by ANOVA with Dunnet's multiple comparison test against the vehicle group.
Neutzsky-Wulff et al. BMC Musculoskeletal Disorders 2010, 11:109
http://www.biomedcentral.com/1471-2474/11/109
Page 8 of 13dered, the osteoclasts will not be able to dig as deep into
the bone as under normal bone resorption (Figure 6,
lower panel) [42,52], which will lead to the observed
decrease in inorganic resorption. In line with this, studies
of bone organ cultures showed that E64 reduced Ca2+
release as well as the expected reduction in organic
resorption [31,53].
Interestingly, we observed that the levels of MMP-gen-
erated type I collagen fragment, ICTP, were elevated
when cathepsin K activity was reduced, whereas the other
inhibitors either left the ICTP level unchanged in com-
parison to vehicle, or lowered the level. These data are in
line with in vivo findings in pycnodysostotic patients,
who have abnormally high levels of ICTP, and with previ-
ous in vitro studies in which E64 was utilized [28,33]. It
should, however, be noted that the basal level of ICTP
release seen in the vehicle condition is in contrast to pre-
viously obtained data [33]. The reason for this discrep-
ancy could be the bone source, as bone of various origin
are resorbed differently [32,36,37]. However, a more likely
explanation is the fact that the levels of ICTP, except for
E64-treated cells, were close to the detection limit and
thus hard to quantify. These data indicate that in the
absence of cathepsin K activity, MMPs may perform
compensatory collagen cleavage, which has previously
been suggested [28,33]. However, as ICTP fragments are
destroyed by cathepsin K [31,54], the MMP turnover pro-
file of type I collagen may be masked under normal phys-
iological bone turnover. However, increased MMP
activity for the E64-treated condition was observed,
which indicates that a compensatory MMP-generated
bone resorption did take place. Thus, it appears that the
increase in ICTP levels is a combination of both an
unmasking and a compensatory effect. These data also
indicate that the effect of cathepsin K inhibitors may be
overestimated when using CTX-I or other cathepsin K-
generated collagen fragments, such as NTX. These colla-
gen fragments specifically monitor the enzymatic activity
of cathepsin K [55] and do not reveal other compensatory
organic resorption processes or the continued resorption
of the inorganic matrix.
The increased area of resorbed bone observed for
osteoclasts treated with E64 is rather surprising. Mea-
surements of cell viability and TRACP activity, did not
suggest that an increased number of osteoclasts was
responsible for the increased resorbed bone area. Previ-
ous studies with E64 did not show an increase in osteo-
clast number either [42]. It is therefore speculated that
the E64-treated osteoclasts are more motile, which could
explain the increased resorbed area. An increased motil-
ity of E64-treated osteoclasts could potentially be
explained by the increased MMP activity in these cells, as
MMPs are known to be associated with cell motility [56].
Supporting this is the observation that GM6001 blunted
the effect of E64 with respect to increased resorbed bone
area, thereby suggesting that MMP activity indeed was
the cause of the elevated resorbed bone surface observed
for E64-treated osteoclasts.
Figure 4 Evaluation of MMP generated resorption and MMP secretion. Mature human osteoclasts were seeded on bone slices and cultured for 
5 days in the presence or absence of the indicated inhibitors. A) ICTP levels were measured in culture supernatants. B) Gelatinase zymografi of pooled 
culture supernatants. MMP-9 is used as marker. A representative gel is shown. Based on analysis of three individual gels in ImageJ, relative band inten-
sities, reflecting MMP-9 activity, were calculated. Relative intensities are given ± SD.
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should be considered to be volumetric rather than areal,
which signifies that an increased resorbed bone surface
does not correlate with increased bone resorption, as this
parameter is clearly lowered for the E64-treated osteo-
clast. As both organic and inorganic resorption was
shown to be lowered by 5 μM E64, despite an increased
resorbed bone area at the same concentration, the
resorption pits are likely more shallow than normal
resorption pits, which is in line with previous studies
[42,52].
The present findings of an increased resorbed bone
area in the presence of E64 correlate well with in vivo
findings in mice, as well as in patients with pycnodysosto-
sis, arising from cathepsin K deficiency, where demineral-
ized areas are observed below the osteoclasts [28,29].
This could also explain why a marked decrease in the
bone resorption markers CTX-I and NTX, by 55-70%,
was seen in cathepsin K inhibitor trials, whereas the
effect on BMD often was less marked (2.5-5.7%) [57,58].
The finding of increased resorbed bone area with E64
treatment is, however, in contrast to a recent study by
Figure 5 The effects of ibandronate on osteoclasts and resorption. Mature human osteoclasts were seeded on bone slices and cultured for 5 days 
in the presence or absence of ibandronate (Iban). A) CTX-I release measured in culture supernatants. B) Calcium release measured in culture superna-
tants. C) Cell viability measured by Alamar Blue. D) TRACP activity measured in culture supernatants. All results are plotted as % of control. Statistical 
tests were performed by ANOVA with Dunnet's multiple comparison test against the vehicle group.
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behavior dependent on the culture substrate, as our study
was performed with cortical bone slices whereas the
other study was conducted with dentine [59].
In our study, ibandronate was found to be a potent
inhibitor of both organic and inorganic bone resorption.
Ibandronate is a nitrogen-containing bisphosphonate
which, like alendronate and risedronate, will bind
strongly to the bone matrix [60-62]. Under acidic condi-
tions, induced by the osteoclasts in the resorption lacuna,
the bound bisphosphonate will be released from the
matrix and in this way target the osteoclasts specifically
[60-62], inducing reduced resorptive activity and apopto-
sis [63,64]. On the other hand, non-resorbing cells, like
macrophages, have been shown not to be greatly affected
by bisphosphonate treatment on dentine, as the cells are
not able to release and take up substantial amounts of the
drug [62]. Ibandronate treatment in our study was shown
to reduce TRACP activity dramatically for all concentra-
tions tested [0.3-100 μM]. This strongly indicates that the
number of mature osteoclasts is reduced dramatically in
these cultures, as strong correlations between TRACP
activity and osteoclast numbers have been reported
[47,48]. However, the overall cell viability of the cultures
was not decreased for most of the tested concentrations.
The discrepancy between low TRACP activity and nor-
mal cell viability can be explained by the presence of mac-
rophages in the culture. When mature osteoclasts are
seeded on bone slices, a portion of these cells will be mac-
rophages [65], which will either proliferate or differenti-
ate into mature osteoclasts. As the macrophages are not
greatly affected by bisphosphonate treatments when cul-
tured on bone [62], this could explain the sustained cell
viability despite a decrease in the number of osteoclasts.
Risedronate, another nitrogen-containing bisphospho-
nate, has been shown to strongly inhibit osteoclastogene-
sis in vitro [66], which could also be the case for
ibandronate, partly explaining the low TRACP levels. If
osteoclast differentiation is inhibited, an increased num-
ber of macrophages would be expected, which could
uphold the cell viability measure. In addition, nitrogen-
containing bisphosphonates are known to induce osteo-
clast apoptosis [63,64], thereby reducing the osteoclast
number. However, the anti-resorptive effect of nitrogen-
Figure 6 Schematic illustration of normal or inhibited osteoclastic resorption. Upper panel: Normal bone resorption with acidification of the re-
sorption lacuna followed by proteolysis for removal of the organic matrix. The resulting pit appearance is shown in the column to the far right. Middle 
panel: Inhibition of acidification leads to disruption of both organic and inorganic resorption. Only residual pits are formed. Lower panel: Inhibition of 
cathepsin K will not prevent inorganic resorption, whereas organic resorption is potently inhibited. The resulting pits will be packed with non-dis-
solved organic matrix, and the pits will have a lower depth than normal pits.
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at concentrations that are lower than for osteoclast apop-
tosis [64]. This could indicate that at lower concentra-
tions, osteoclast apoptosis is not induced, despite
attenuation of the resorptive activity. Nitrogen-contain-
ing bisphosphonates inhibit farnesyl diphosphate (FPP)
synthase, which attenuates osteoclast function, in part by
disrupting vesicular transport [63,67]. As release of
TRACP from mature osteoclasts is dependent on vesicu-
lar trafficking [68], the reduced TRACP activity might
also reflect this issue at concentrations where osteoclast-
specific apoptosis is not induced. The three scenarios:
decreased osteoclastogenesis, osteoclast apoptosis and
obstruction of TRACP release, could therefore all poten-
tially be involved in the reduction of TRACP activity, and
it would be of interest to examine these aspects further.
However, regardless of the mechanism for lowering the
osteoclast number or attenuation of resorptive activity,
the resorptive profile is clear: both organic and inorganic
bone resorption are abrogated at ibandronate concentra-
tions of 1 μM and higher (Figure 5).
Recent studies have indicated that the osteoclast phe-
notype is important for the control of bone remodeling
[4,7]. Osteoclasts likely control bone formation both
directly by secretion of molecules with anabolic effects on
osteoblasts, but also through the modulation of the sur-
face of the resorption pits, which is dramatically altered
when cathepsin K activity is absent [4,7,8]. The different
mode of actions of the utilized osteoclast inhibitors can
therefore be speculated to have different treatment pro-
files when used as, for example, treatments of osteoporo-
sis. All anti-resorptive drugs currently used in clinical
settings display reduced fracture risks due to abrogation
of osteoclast functionality, which leads to lower activa-
tion frequency of new remodeling sites. However, differ-
ences between treatments exist. Bisphosphonates are
associated with a big drop in osteoclast number, strongly
reduced bone resorption and secondarily a strong reduc-
tion in bone formation [69]. A recent study with odana-
catib, a specific cathepsin K inhibitor, has demonstrated a
strong decrease in bone resorption, an initial drop in
bone formation, which subsequently increased towards
the baseline level [58]. This indicates that in this type of
treatment, a strong coupling between resorption and for-
mation is not seen as in the case of bisphosphonate treat-
ments [58]. This could potentially be due to maintenance
of osteoclasts within the bones when cathepsin K is tar-
geted, in contrast to treatments with bisphosphonates.
However, the clinical study with odanacatib demon-
strated that the resorption surface was unaltered in the
treatment groups in comparison to the placebo group
[58]. This finding, that initiation of bone resorption is
continued despite inhibition of cathepsin K, was con-
firmed in the present study. No clinical trials have so far
been conducted with acidification inhibitors, however,
animal studies demonstrate that bone resorption can be
lowered with these agents, without a subsequent lower-
ing of bone formation [51]. Furthermore, it can be specu-
lated that treatment with acidification blockers could lead
to a higher increase in BMD, in comparison to treatments
with cathepsin K inhibitors, as resorption of the inorganic
matrix is prohibited.
Conclusions
In conclusion, we examined the osteoclast phenotype in
response to inhibition of acidification, proteolysis or gen-
eral osteoclast inhibition. We found that inhibition of
acidification, leading to inhibited dissolution of the inor-
ganic bone matrix, completely shut down the ability of
osteoclasts to resorb bone as a whole. In contrast, inhibi-
tion of the cysteine proteinases strongly reduced release
of CTX-I, but might allow compensatory bone resorption
by MMPs, and inorganic resorption was only modestly
reduced. An illustration of our proposed mechanism of
osteoclast action is given in Figure 6, illustrating both
inhibition of acidification and proteolysis. Ibandronate
was shown to be a potent inhibitor of all aspects of bone
resorption, by specifically reducing the number of mature
osteoclasts. Taken together, bone resorption inhibitors
may induce different osteoclast phenotypes that may be
associated with different osteoclast qualities. As osteo-
clast number and quality are believed to be important for
bone quality, investigation and understanding of these
parameters for osteoporosis intervention therapies may
provide additional information and understanding of the
effect on skeletal health.
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